Floatz logo

18F-ASIS

Soft Tissue Sarcoma (STS)

Var2 PharmaceuticalsEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Soft Tissue Sarcoma (STS) cohort.

Asset / SponsorPhaseRating
gi-102
GI Innovation, Inc.
Phase 1/2CC
Trastuzumab Deruxtecan
GI Innovation, Inc.
Phase 1/2CC
68ga-dfc413
Novartis Pharmaceuticals
Phase 1CC
MDG1015
Medigene AG
Phase 1CC
89zr-dfo-n-suc-c9scfv
Var2 Pharmaceuticals
Early Phase 1C
89Zr-DFO-N-Suc-F8scFv
Var2 Pharmaceuticals
Early Phase 1C

Same molecule, other indications

18F-ASIS is also rated in:

Inflammatory Demyelinating DiseaseDormant
CCC
Indicative ·
53 / 100
View asset →
Thymus NeoplasmsDormant
CCC
Indicative ·
53 / 100
View asset →
Non-small Cell Lung CancerDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →